4,927 reports of this reaction
2.4% of all BUPROPION HYDROCHLORIDE reports
#8 most reported adverse reaction
DIZZINESS is the #8 most commonly reported adverse reaction for BUPROPION HYDROCHLORIDE, manufactured by Bausch Health US LLC. There are 4,927 FDA adverse event reports linking BUPROPION HYDROCHLORIDE to DIZZINESS. This represents approximately 2.4% of all 208,986 adverse event reports for this drug.
Patients taking BUPROPION HYDROCHLORIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for BUPROPION HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for BUPROPION HYDROCHLORIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 4,927 FDA reports for BUPROPION HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.4% of all adverse event reports for BUPROPION HYDROCHLORIDE, making it a notable side effect.
If you experience dizziness while taking BUPROPION HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.